Analyses of Real World Data on Overall Survival in Multiple Myeloma Patients with at Least 3 Prior Lines of Therapy Including a PI and an IMiD, or Double Refractory to a PI and an IMiD
Author:
Saad Usmani,Tahamtan Ahmadi,Yvette Ng,Annette Lam,Ravi Potluri,Maneesha Mehra
Copyright © 2015 American Society of Hematology